Bio

Honors & Awards


  • Post-doctoral Fellow, Stanford Spectrum KL2 Mentored Career Development Award (10/2015-)
  • Research Fellow, Doris Duke International Clinical Research Fellowship (7/2008-6/2009)

Boards, Advisory Committees, Professional Organizations


  • Member, IDSA (2015 - Present)

Professional Education


  • Internship, New York University, Internal Medicine (2011)
  • Residency, New York University, Internal Medicine (2013)
  • Doctor of Medicine, University of California San Francisco (2010)
  • Bachelor of Science, University of California Davis (2004)

Stanford Advisors


Service, Volunteer and Community Work


  • Physician, PACE Clinic - Santa Clara Valley Medical Center

    Provide care for patients with HIV/AIDS

    Location

    San Jose, CA

Teaching

Graduate and Fellowship Programs


Publications

All Publications


  • Fidaxomicin versus Conventional Antimicrobial Therapy in 59 Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation with Clostridium difficile-Associated Diarrhea ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Clutter, D. S., Dubrovskaya, Y., Merl, M. Y., Teperman, L., Press, R., Safdar, A. 2013; 57 (9): 4501-4505

    Abstract

    The feasibility of fidaxomicin versus vancomycin and metronidazole (conventional therapy) was assessed in 59 transplant recipients with 61 episodes of Clostridium difficile-associated diarrhea (CDAD). Overall clinical cure was achieved in 86% of episodes, and in 7% of episodes, infection recurred. Fidaxomicin was well tolerated. Clinical cures were not significantly different compared with conventional therapy (67% versus 89%, respectively; P = 0.06). Univariate analysis of predictors for lack of clinical cure included continued use of broad-spectrum systemic antibiotics (P = 0.026) and prior diagnosis of CDAD (95% confidence interval, 1.113 to 19.569; odds ratio, 4.667; P = 0.041). New-onset vancomycin-resistant Enterococcus (VRE) colonization was not noted after fidaxomicin therapy alone. However, this occurred in 10 of 28 patients (36%) following conventional therapy, and 2 of 3 patients with subsequent bacteremia died.

    View details for DOI 10.1128/AAC.01120-13

    View details for Web of Science ID 000323285500052

    View details for PubMedID 23836168

  • Investigation of a novel, heritable bleeding diathesis of thoroughbred horses and development of a screening assay JOURNAL OF VETERINARY INTERNAL MEDICINE Norris, J. W., Pratt, S. M., Auh, J., Wilson, S. J., Clutter, D., Magdesian, K. G., Ferraro, G. L., Tablin, F. 2006; 20 (6): 1450-1456

    Abstract

    Bleeding in racing horses associated with exercise appears to be multifactorial, and clinical investigation into severe cases rarely occurs. Previously, we reported a severe bleeding diathesis in a Thoroughbred mare. Herein, we describe the cellular physiology of this defect, provide a diagnostic tool for identifying it, and demonstrate that the dysfunction is heritable.The subject has a heritable defect in platelet secretion that reduces thrombin generation in the absence of additional plasma factors and delays the onset of thrombin production even in the presence of these factors.The study included 3 clinically normal Thoroughbred horses: the subject and her offspring.Washed platelets were examined for their ability to (1) translocate phosphatidylserine to the outer leaflet of the platelet membrane as determined by annexin-V binding, (2) generate thrombin as assessed by the activity of the prothrombinase enzyme complex, and (3) bind fibrinogen and form aggregates as determined by flow cytometry.Subject and offspring platelets created procoagulant surfaces by translocating phosphatidylserine. The subject's platelets demonstrated reduced prothrombinase activity, resulting in decreased production of thrombin relative to control platelets. Subject and offspring platelets bound less fibrinogen than control platelets when stimulated with thrombin.The subject mare has a transmissible defect that involves reduced generation of thrombin by activated platelets, resulting in decreased aggregation and ineffective clotting. A flow cytometric assay of fibrinogen binding to washed platelets discriminates individuals with this platelet dysfunction and may be useful for discerning subclinical congenital or acquired platelet dysfunctions.

    View details for Web of Science ID 000242567200028

    View details for PubMedID 17186864

Footer Links:

Stanford Medicine Resources: